Bausch Health Companies Inc.

BHC

CA0717341071

Pharmaceuticals

Market Closed - Nyse Other stock markets 16:00:02 2024-07-17 EDT			5-day change	1st Jan Change
7.62 ^USD	+0.93%		+4.10%	-4.99%

07-10	Raymond James Initiates Bausch Health at Market Perform Rating	MT
06-21	Bausch Health Sues Norwich for Patent Infringement Over Application for Generic Version of IBS Drug	MT

Valeant Plans To Sell Its $2.1 Billion In Assets

January 10, 2017 at 12:00 am

Valeant Pharmaceuticals International, Inc. (NYSE:VRX) plans to sell $2.1 billion in assets as it seeks to trim its better than $30 billion in debt.

Latest news about Bausch Health Companies Inc.

Raymond James Initiates Bausch Health at Market Perform Rating	07-10	MT
Bausch Health Sues Norwich for Patent Infringement Over Application for Generic Version of IBS Drug	06-21	MT
Bausch + Lomb Brief: To Present New Data at European Dry Eye Society 2024 Congress; Events Include Symposium on Patient-Centric Approaches to Dry Eye, "Highlighting Breakthroughs in Diagnosis, Treatment and Care"	06-17	MT
Bausch + Lomb Brief: Launching "Clinically Proven" Nutritional Supplement for Dry Eyes in the United States	06-03	MT
Bausch + Lomb Brief: Says Received Health Canada Approval for Full Visual Range Intraocular Lens	05-28	MT
Bausch Health Announces Wider Public Drug Plan Coverage for Uceris in Canada	05-23	MT
Bausch Health Companies Inc. and Salix Pharmaceuticals to Present Late-Breaking Data from Phase 2 Trial of Amiselimod in Active Ulcerative Colitis at Digestive Disease Week 2024	05-17	CI
RBC Notes Updates on Bausch Xifaxan Patent Litigation with Norwich	05-15	MT
Bausch Health Companies Inc. Approves Directorate Appointments	05-15	CI
Bausch Health Down 6.6% In US After Hours As Updates Related to Norwich XIFAXAN Matters	05-14	MT
Bausch Health Brief: Announcing Updates Related to Norwich XIFAXAN Matters	05-14	MT
RBC Noes Bausch Health Filing For Rehearing in Appellate Court	05-13	MT
RBC Lowers Bausch Health Target to US$10, Maintains Sector Perform	05-03	MT
Bausch Health Shares Fall Following Q1 Results	05-02	MT
Bausch Health Q1 Net Loss Narrows on Higher Revenue, Confirms 2024 Revenue Guidance	05-02	MT
Transcript : Bausch Health Companies Inc., Q1 2024 Earnings Call, May 02, 2024	05-02
Bausch Health Brief: Reaffirmed full-year Revenue and Adjusted EBITDA (non-GAAP) guidance	05-02	MT
Bausch Health Brief: Q1 revenues of US$2.15 billion, up 11% on a Reported and 8% on an Organic basis	05-02	MT
Bausch Health Companies Inc. Reaffirms Earnings Guidance for the Full Year 2024	05-02	CI
Bausch Health Companies Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-02	CI
North American Morning Briefing : Stock Futures -2-	05-02	DJ
Needham Says Bausch + Lomb's Q1 Showed a "Strong Start" to The Year	05-01	MT
Bausch + Lomb Brief: Raising Full-Year 2024 Constant Currency Revenue Growth Guidance	05-01	MT
Bausch + Lomb Brief: Q1 Adjusted EBITDA (non-GAAP) of US$180 Million	05-01	MT
Bausch + Lomb Brief: Q1 Revenue of US$1.099 Billion; GAAP Net Loss Attributable of $167 Million	05-01	MT

Chart Bausch Health Companies Inc.

Duration

Period

More charts

Bausch Health Companies Inc. is a global diversified pharmaceutical company. The Company develops, manufactures, and markets a range of products primarily in gastroenterology (GI), hepatology, neurology, dermatology, eye health, and others, through Bausch + Lomb Corporation. Its Salix segment consists of sales in the United States of GI products. Its International segment consists of sales, with the exception of sales of Bausch + Lomb products and Solta Medical aesthetic medical devices, outside the United States and Puerto Rico of branded pharmaceutical products, branded generic pharmaceutical products and other products. Its Solta Medical segment consists of global sales of Solta Medical aesthetic medical devices. Its Diversified segment consists of sales in the United States of pharmaceutical products in the areas of neurology and certain other therapeutic classes. Its Bausch + Lomb segment consists of global sales of Bausch + Lomb Vision Care, surgical and pharmaceutical products.

Sector

Pharmaceuticals

Calendar

2024-07-31 - Q2 2024 Earnings Release

More about the company

Income Statement Evolution

More financial data

Ratings for Bausch Health Companies Inc.

Trading Rating

Investor Rating

ESG Refinitiv

C+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

HOLD

Number of Analysts

Last Close Price

7.62 USD

Average target price

9.562 USD

Spread / Average Target

+25.49%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
BAUSCH HEALTH COMPANIES INC.	-4.99%	2.77B
ELI LILLY AND COMPANY	+55.35%	848B
NOVO NORDISK A/S	+31.64%	627B
JOHNSON & JOHNSON	-0.10%	363B
MERCK & CO., INC.	+15.47%	318B
ABBVIE INC.	+13.10%	299B
ASTRAZENECA PLC	+15.51%	243B
NOVARTIS AG	+16.72%	225B
AMGEN INC.	+16.54%	179B
PFIZER, INC.	+4.31%	167B

Other Pharmaceuticals

Bausch Health Companies Inc.

Equities

BHC

CA0717341071

Pharmaceuticals

Valeant Plans To Sell Its $2.1 Billion In Assets

Latest news about Bausch Health Companies Inc.

Chart Bausch Health Companies Inc.

Company Profile

Income Statement Evolution

Ratings for Bausch Health Companies Inc.

Analysts' Consensus

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Other Pharmaceuticals